

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Accord Healthcare Inc. and Apotex Inc. that the shortages for Ach-Olmesartan HCTZ 40 mg/12.5 mg Tablet (DIN 02468956) and Apo-Olmesartan/HCTZ 40 mg/12.5 mg Tablet (DIN 02453614) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 21, 2020**. The following grouping was removed from the Critical Supply Product List **August 21, 2020**.

### OLMESARTAN MEDOXOMIL / HYDROCHLOROTHIAZIDE

#### 40 MG / 12.5 MG TABLET

|             |                      |     |           |
|-------------|----------------------|-----|-----------|
| 00002468956 | ACH-OLMESARTAN HCTZ  | AHI | \$ 0.3019 |
| 00002443120 | ACT OLMESARTAN HCT   | APH | \$ 0.3019 |
| 00002453614 | APO-OLMESARTAN/HCTZ  | APX | \$ 0.3019 |
| 00002476495 | AURO-OLMESARTAN HCTZ | AUR | \$ 0.3019 |
| 00002319624 | OLMETEC PLUS         | MFC | \$ 1.1441 |

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Lenoltec No.3 Tablet (DIN 00653276) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 24, 2020**. The following grouping was removed from the Critical Supply Product List **August 25, 2020**.

### CODEINE PHOSPHATE / ACETAMINOPHEN / CAFFEINE

#### 30 MG / 300 MG / 15 MG TABLET

|             |                    |     |           |
|-------------|--------------------|-----|-----------|
| 00000653276 | TEVA-LENOLTEC NO.3 | TEV | \$ 0.0889 |
| 00002163926 | TYLENOL NO. 3      | JAI | \$ 0.1217 |

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Imiquimod Pump 5% Topical Cream (DIN 02482983) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 24, 2020**. The following grouping was removed from the Critical Supply Product List **August 25, 2020**.

### IMIQUIMOD

#### 50 MG / G TOPICAL CREAM

|             |                     |     |            |
|-------------|---------------------|-----|------------|
| 00002482983 | TARO-IMIQUIMOD PUMP | TAR | \$ 43.4350 |
| 00002239505 | ALDARA P            | VCL | \$ 52.9314 |

... continued from previous page

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Triaderm Regular 0.1% Topical Cream (DIN 00716960) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 28, 2020**. The following grouping was removed from the Critical Supply Product List **August 26, 2020**.

#### TRIAMCINOLONE ACETONIDE

##### 0.1 % TOPICAL CREAM

|             |                  |     |           |
|-------------|------------------|-----|-----------|
| 00000716960 | TRIADERM REGULAR | TAR | \$ 0.1024 |
| 00002194058 | ARISTOCORT R     | VCL | \$ 0.1420 |

Alberta Blue Cross has been advised by Apotex Inc. and Teva Canada Limited that the shortages of Apo-Sucralfate 1 g Tablet (DIN 02125250) and Teva-Sucralfate 1 g Tablet (DIN 02045702) respectively, have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 28, 2020**. The following grouping was removed from the Critical Supply Product List **August 28, 2020**.

#### SUCRALFATE

##### 1 G ORAL TABLET

|             |                 |     |           |
|-------------|-----------------|-----|-----------|
| 00002125250 | APO-SUCRALFATE  | APX | \$ 0.3089 |
| 00002045702 | TEVA-SUCRALFATE | TEV | \$ 0.3089 |
| 00002100622 | SULCRATE        | AXC | \$ 0.6399 |

## Removal of temporary benefit from the *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Due to the shortage of Salinex 0.9% Nasal Solution (Drops) (NPN 80024901) manufactured by Exzell Pharma, Salinex 9 mg/ml Nasal Spray (NPN 80024381) manufactured by Exzell Pharma was added as a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*.

Exzell Pharma has advised Alberta Blue Cross that the shortage of Salinex 0.9% Nasal Solution (Drops) (NPN 80024901) has been resolved. As a result, Salinex 9 mg/ml Nasal Spray (NPN 80024381) will no longer be considered a temporary benefit for the HSDBS after **September 28, 2020**. These products were removed from the Critical Supply Product List **August 27, 2020**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area)  
403-294-4041 (Calgary and area)  
1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)  
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

